Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.46 |
| ▸ | HTR2A | P28223 | 13/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.46 |
| ▸ | HTR1A | P08908 | 11/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726294 | 0.79 | DRD2 (0.54) | DRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL4729622 | 0.78 | DRD2 (0.57) | DRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL26770363 | 0.75 | HTR2C (0.47) | HTR2APARP15PARP10 | |
| SCHEMBL31158741 | 0.74 | HTR2A (0.42) | DRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL26770373 | 0.73 | HTR2C (0.44) | HTR2ASLC6A4PARP15PARP10 | |
| SCHEMBL26770383 | 0.73 | HTR2A (0.44) | HTR2ASLC6A4PARP15PARP10 | |
| SCHEMBL29875305 | 0.71 | AURKA (0.40) | DRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL24170303 | 0.70 | HTR2C (0.44) | HTR2APARP15PARP10 | |
| SCHEMBL16501544 | 0.70 | SLC6A4 (0.47) | HTR2ASLC6A4PARP15PARP10 | |
| SCHEMBL12240957 | 0.67 | CLK4 (0.43) | DRD2HTR2ASLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010054278-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | DRD2 4803/4885HTR2A 4604/4885SLC6A4 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.